LISATA THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
LISATA THERAPEUTICS, INC. (LSTA) reported Cash and Cash Equivalents, Period Increase (Decrease) of $8.34 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-10.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-08-10
- LISATA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $11.05M.
- LISATA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$2.71M, a 153.01% decline year-over-year.
- LISATA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was -$3.90M.
- LISATA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was $907.06K.
- LISATA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$5.61M, a 590.53% decline from fiscal 2015.
- LISATA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $1.14M.
- LISATA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$26.96M, a 183.22% decline from fiscal 2013.
- LISATA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2013 was $32.40M, a 3165.69% increase from fiscal 2012.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-06-30 | $11.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $8.34M 10-Q · filed 2017-08-10 | $4.44M derived: sum of 3 quarters · filed 2017-08-10 | $5.35M derived: sum of 4 quarters · filed 2017-08-10 |
| 2017-03-31 | -$2.71M 10-Q · filed 2017-05-15 | -$6.61M derived: sum of 2 quarters · filed 2017-05-15 | -$5.70M derived: sum of 3 quarters · filed 2017-05-15 | -$13.43M derived: sum of 4 quarters · filed 2017-08-10 |
| 2016-12-31 | -$3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-17 | -$2.99M derived: sum of 2 quarters · filed 2017-03-17 | -$10.72M derived: sum of 3 quarters · filed 2017-08-10 | -$5.61M 10-K · filed 2017-03-17 |
| 2016-09-30 | $907.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$6.82M derived: sum of 2 quarters · filed 2017-08-10 | -$1.71M 10-Q · filed 2016-11-07 | -$5.44M derived: sum of 4 quarters · filed 2017-08-10 |
| 2016-06-30 | -$7.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$2.62M 10-Q · filed 2017-08-10 | -$6.34M derived: sum of 3 quarters · filed 2017-08-10 | -$18.51M derived: sum of 4 quarters · filed 2017-08-10 |
| 2016-03-31 | $5.11M 10-Q · filed 2017-05-15 | $1.38M derived: sum of 2 quarters · filed 2017-05-15 | -$10.79M derived: sum of 3 quarters · filed 2017-05-15 | $6.29M derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | -$3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-17 | -$15.89M derived: sum of 2 quarters · filed 2017-03-17 | $1.19M derived: sum of 3 quarters · filed 2017-03-17 | $1.14M 10-K · filed 2017-03-17 |
| 2015-09-30 | -$12.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $4.91M derived: sum of 2 quarters · filed 2016-11-07 | $4.87M 10-Q · filed 2016-11-07 | -$8.10M derived: sum of 4 quarters · filed 2016-11-07 |
| 2015-06-30 | $17.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $17.04M 10-Q · filed 2016-08-09 | $4.07M derived: sum of 3 quarters · filed 2016-08-09 | $3.35M derived: sum of 4 quarters · filed 2016-08-09 |
| 2015-03-31 | -$42.78K 10-Q · filed 2016-05-05 | -$13.01M derived: sum of 2 quarters · filed 2016-05-05 | -$13.73M derived: sum of 3 quarters · filed 2016-05-05 | -$22.23M derived: sum of 4 quarters · filed 2016-05-05 |
| 2014-12-31 | -$12.97M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$13.69M derived: sum of 2 quarters · filed 2016-03-15 | -$22.19M derived: sum of 3 quarters · filed 2016-03-15 | -$26.96M 10-K · filed 2016-03-15 |
| 2014-09-30 | -$723.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$9.22M derived: sum of 2 quarters · filed 2015-11-05 | -$13.99M 10-Q · filed 2015-11-05 | $15.20M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-06-30 | -$8.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$13.27M 10-Q · filed 2015-08-06 | $15.92M derived: sum of 3 quarters · filed 2016-03-15 | $18.14M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-03-31 | -$4.77M 10-Q · filed 2015-05-06 | $24.41M derived: sum of 2 quarters · filed 2016-03-15 | $26.64M derived: sum of 3 quarters · filed 2016-03-15 | $32.11M derived: sum of 4 quarters · filed 2016-03-15 |
| 2013-12-31 | $29.19M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $31.41M derived: sum of 2 quarters · filed 2016-03-15 | $36.88M derived: sum of 3 quarters · filed 2016-03-15 | $32.40M 10-K · filed 2016-03-15 |
| 2013-09-30 | $2.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | $7.69M derived: sum of 2 quarters · filed 2014-10-30 | $3.21M 10-Q · filed 2014-10-30 | $766.11K derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $5.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $985.03K 10-Q · filed 2014-08-07 | -$1.46M derived: sum of 3 quarters · filed 2015-03-02 | -$3.54M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | -$4.48M 10-Q · filed 2014-05-08 | -$6.93M derived: sum of 2 quarters · filed 2015-03-02 | -$9.01M derived: sum of 3 quarters · filed 2015-03-02 | -$12.62M derived: sum of 4 quarters · filed 2015-03-02 |
| 2012-12-31 | -$2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$4.52M derived: sum of 2 quarters · filed 2015-03-02 | -$8.14M derived: sum of 3 quarters · filed 2015-03-02 | $992.02K 10-K · filed 2015-03-02 |
| 2012-09-30 | -$2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$5.69M derived: sum of 2 quarters · filed 2013-11-07 | $3.43M 10-Q · filed 2013-11-07 | $4.47M derived: sum of 4 quarters · filed 2013-11-07 |
| 2012-06-30 | -$3.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $5.52M 10-Q · filed 2013-08-08 | $6.55M derived: sum of 3 quarters · filed 2013-08-08 | $13.41M derived: sum of 4 quarters · filed 2013-08-08 |
| 2012-03-31 | $9.13M 10-Q · filed 2013-05-09 | $10.16M derived: sum of 2 quarters · filed 2013-05-09 | $17.02M derived: sum of 3 quarters · filed 2013-05-09 | $12.46M derived: sum of 4 quarters · filed 2013-05-09 |
| 2011-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $7.90M derived: sum of 2 quarters · filed 2013-03-11 | $3.33M derived: sum of 3 quarters · filed 2013-03-11 | -$2.87M 10-K · filed 2013-03-11 |
| 2011-09-30 | $6.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13 | $2.30M derived: sum of 2 quarters · filed 2012-11-13 | -$3.90M 10-Q · filed 2012-11-13 | $7.65M derived: sum of 4 quarters · filed 2012-11-13 |
| 2011-06-30 | -$4.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | -$10.76M 10-Q · filed 2012-08-14 | $783.72K derived: sum of 3 quarters · filed 2012-08-15 | -$6.11M derived: sum of 4 quarters · filed 2012-08-15 |
| 2011-03-31 | -$6.20M 10-Q · filed 2012-05-11 | $5.35M derived: sum of 2 quarters · filed 2012-08-15 | -$1.55M derived: sum of 3 quarters · filed 2012-08-15 | |
| 2010-12-31 | $11.55M derived: 8-K 12 month − 10-Q 9 month · filed 2012-08-15 | $4.65M derived: sum of 2 quarters · filed 2012-08-15 | $8.45M 8-K · filed 2012-08-15 | |
| 2010-09-30 | -$6.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | -$3.09M 10-Q · filed 2011-11-10 | ||
| 2010-06-30 | $3.80M 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |